Medical School · Year 3 · Psychiatry · includes a quiz and discussion video

Seminar 04: Anxiety Disorders

Year 3: Psychiatry Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Differentiate types of anxiety disorders
2. Diagnose generalized anxiety disorder and panic disorder
3. Recognize specific phobia and social anxiety disorder
4. Apply pharmacological treatment principles
5. Describe cognitive behavioral therapy for anxiety
6. Manage acute anxiety presentations

Seminar Outline

I. Overview of Anxiety Disorders

Anxiety disorders collectively represent the most common category of mental disorders, affecting approximately twenty-eight to thirty percent of the population at some point during their lifetime. These conditions are characterized by excessive fear and anxiety along with related behavioral disturbances that cause significant distress and functional impairment. Fear represents an emotional response to a real or perceived imminent threat, while anxiety is anticipation of future threat. Women are affected approximately twice as frequently as men across most anxiety disorders, a disparity that emerges during adolescence. The typical age of onset for most anxiety disorders falls in childhood or adolescence, earlier than most other mental disorders.

The spectrum of anxiety disorders encompasses several distinct conditions, each with characteristic features and clinical presentations. Generalized anxiety disorder involves excessive worry about multiple life domains persisting for at least six months. Panic disorder features recurrent unexpected panic attacks followed by persistent concern about additional attacks or maladaptive behavioral changes. Social anxiety disorder involves marked fear of social situations in which the individual may be scrutinized by others. Specific phobia describes marked fear of a particular object or situation. Agoraphobia involves fear of situations where escape might be difficult or help unavailable if panic-like symptoms occur. Separation anxiety disorder, though more common in children, may persist into or begin in adulthood.

Distinguishing normal from pathological anxiety requires consideration of proportionality, adaptiveness, duration, and functional impact. Normal anxiety is proportionate to the actual threat, serves adaptive functions by motivating preparation and protective behavior, is time-limited, manageable, and does not cause significant functional impairment. Pathological anxiety is excessive relative to the actual threat, causes clinically significant distress or impairment in social, occupational, or other important areas of functioning, is persistent rather than transient, and overwhelms the individual's capacity to cope. The distinction is dimensional rather than categorical, with anxiety disorders representing the severe end of a continuous distribution.

The neurobiology of anxiety disorders involves multiple brain systems and neurotransmitter systems. The amygdala serves as the central hub for fear processing and is hyperactive in anxiety disorders, showing exaggerated responses to threatening stimuli. The prefrontal cortex normally provides top-down regulation of amygdala activity, but this regulatory function may be impaired in anxiety. The hypothalamic-pituitary-adrenal axis mediates the physiological stress response and may show dysregulation. GABAergic inhibitory neurotransmission is reduced in anxiety, which explains the efficacy of benzodiazepines that enhance GABA function. Serotonergic systems modulate anxiety, providing the rationale for SSRI treatment.

<image>Panel A: A bar graph showing lifetime prevalence of different anxiety disorders by gender. Panel B: A diagram illustrating the fear circuit including amygdala, prefrontal cortex, and hypothalamus. Panel C: A comparison chart showing features distinguishing normal from pathological anxiety. Panel D: A neurotransmitter diagram showing roles of GABA and serotonin in anxiety modulation.</image>

II. Generalized Anxiety Disorder

Generalized anxiety disorder is characterized by excessive anxiety and worry about a number of events or activities, occurring more days than not for at least six months. The individual finds it difficult to control the worry, which distinguishes GAD from normal concern about life circumstances. The worry must be associated with at least three of six additional symptoms in adults, or only one symptom in children, from the following list: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. The anxiety, worry, or physical symptoms must cause clinically significant distress or impairment.

The content of worry in GAD typically encompasses multiple domains of life rather than focusing on a single concern. Common worry topics include health of self and family members, financial matters, job performance and security, school performance, and relationships. The worry often takes the form of "what if" catastrophic thinking, anticipating unlikely negative outcomes and dwelling on worst-case scenarios. Physical symptoms including headaches, gastrointestinal disturbances, and muscle tension frequently dominate the clinical presentation, particularly in primary care settings. Patients often present with somatic complaints without recognizing the underlying anxiety.

Reassurance-seeking behavior characterizes many patients with GAD, who repeatedly ask family members or healthcare providers for confirmation that feared outcomes will not occur. While reassurance provides temporary relief, the relief is short-lived, and the reassurance-seeking pattern perpetuates the anxiety by preventing learning that uncertainty can be tolerated. Avoidance behavior may develop as patients attempt to escape or prevent situations that trigger worry. Perfectionistic tendencies and difficulty tolerating uncertainty underlie much GAD psychopathology and represent important treatment targets.

Differential diagnosis requires distinguishing GAD from other conditions that may present with anxiety. Medical conditions including hyperthyroidism, cardiac arrhythmias, and excessive caffeine intake can produce anxiety symptoms and should be ruled out. Panic disorder involves discrete, unexpected panic attacks as the primary feature rather than chronic worry. Social anxiety disorder focuses specifically on fear of negative evaluation in social situations. Depression commonly co-occurs with GAD and may present with similar symptoms including concentration difficulty and sleep disturbance. Obsessive-compulsive disorder involves intrusive obsessive thoughts and ritualistic compulsions rather than excessive worry about real-life concerns.

<image>Panel A: A checklist display of DSM-5 criteria for generalized anxiety disorder with duration and symptom count requirements. Panel B: A thought bubble diagram showing common worry domains in GAD including health, finances, work, and relationships. Panel C: A cycle diagram illustrating the reassurance-seeking pattern and its perpetuation of anxiety. Panel D: A differential diagnosis flowchart distinguishing GAD from medical conditions and other anxiety disorders.</image>

III. Panic Disorder

A panic attack is defined as an abrupt surge of intense fear or intense discomfort that reaches a peak within minutes, during which time four or more of thirteen specified symptoms occur. Panic attacks may be expected, occurring in response to a known trigger, or unexpected, occurring without any obvious cue. The symptoms of panic attacks include both physical and cognitive manifestations. Physical symptoms include palpitations or pounding heart, sweating, trembling or shaking, sensations of shortness of breath or smothering, feelings of choking, chest pain or discomfort, nausea or abdominal distress, dizziness or lightheadedness, chills or hot flashes, and paresthesias. Cognitive symptoms include derealization or depersonalization, fear of losing control or going crazy, and fear of dying.

Panic disorder requires recurrent unexpected panic attacks, with at least one attack followed by one month or more of either persistent concern about additional panic attacks or their consequences, or significant maladaptive change in behavior related to the attacks such as avoidance of exercise or unfamiliar situations. The disturbance must not be attributable to substances, medical conditions, or other mental disorders. Panic attacks themselves are not a mental disorder but rather a symptom that can occur in the context of various anxiety and other disorders. The diagnosis of panic disorder specifically requires unexpected attacks plus the anticipatory anxiety or behavioral changes.

The clinical course of panic disorder often follows a characteristic progression from initial panic attacks through development of anticipatory anxiety and avoidance behavior. The first panic attack often occurs during a period of stress and may be attributed to a medical emergency, leading to emergency department visits and medical workups. As attacks recur, patients develop persistent concern about having additional attacks and may begin avoiding situations where attacks have occurred or where they fear attacks might occur. This avoidance can progressively narrow the patient's activities and may lead to agoraphobia, which develops in thirty to fifty percent of panic disorder patients.

Complications of panic disorder extend beyond the attacks themselves to include significant medical utilization, functional impairment, and psychiatric comorbidity. Patients with panic disorder frequently present to emergency departments and primary care settings with concerns about heart attacks, strokes, or other medical emergencies. The repeated medical evaluations and resulting negative workups add healthcare costs without addressing the underlying condition. Depression develops as a comorbid condition in approximately half of patients with panic disorder. Substance use disorders, particularly alcohol use disorder, may develop as patients attempt to self-medicate their anxiety. Suicidal ideation occurs more frequently in panic disorder patients than in the general population.

<image>Panel A: A body diagram showing the thirteen symptoms of panic attacks organized by physical and cognitive domains. Panel B: A timeline illustrating the progression from initial panic attacks through anticipatory anxiety to agoraphobia. Panel C: A flowchart showing DSM-5 diagnostic criteria for panic disorder including unexpected attacks plus worry or behavioral change. Panel D: A diagram of panic disorder complications including medical utilization, depression, and substance use.</image>

IV. Agoraphobia and Specific Phobia

Agoraphobia involves marked fear or anxiety about two or more of five situation types: using public transportation such as buses, trains, or planes; being in open spaces such as parking lots, marketplaces, or bridges; being in enclosed spaces such as shops, theaters, or cinemas; standing in line or being in a crowd; and being outside of the home alone. The individual fears or avoids these situations because of thoughts that escape might be difficult or help might not be available in the event of developing panic-like symptoms or other incapacitating or embarrassing symptoms. The situations almost always provoke fear or anxiety and are actively avoided, require the presence of a companion, or are endured with intense fear or anxiety. The fear is out of proportion to the actual danger and persists for at least six months.

The relationship between agoraphobia and panic disorder has been reconceptualized in DSM-5, which now treats agoraphobia as a separate diagnosis that may or may not co-occur with panic disorder. Historically, agoraphobia was considered primarily a complication of panic disorder, but research demonstrates that agoraphobia can develop without history of panic attacks and that panic disorder and agoraphobia follow somewhat different courses. When both conditions are present, both diagnoses should be assigned. The severity of agoraphobia ranges from mild limitation to complete inability to leave home, with some severely affected individuals becoming essentially housebound.

Specific phobia involves marked fear or anxiety about a specific object or situation, such as flying, heights, animals, receiving an injection, or seeing blood. The phobic object or situation almost always provokes immediate fear or anxiety, is actively avoided or endured with intense distress, and the fear is out of proportion to the actual danger. The fear, anxiety, or avoidance persists for at least six months and causes clinically significant distress or impairment. Specific phobia represents the most common anxiety disorder, affecting approximately eight to twelve percent of the population, though many affected individuals do not seek treatment because they can simply avoid the phobic stimulus.

Specific phobias are categorized into subtypes based on the nature of the feared object or situation. Animal type involves fear of animals or insects such as spiders, dogs, or snakes. Natural environment type involves fear of situations in the natural environment such as heights, storms, or water. Blood-injection-injury type involves fear of seeing blood, receiving injections, or having invasive medical procedures. Situational type involves fear of specific situations such as airplanes, elevators, or enclosed places. Other type includes all other phobias such as fear of choking, vomiting, or contracting an illness. The blood-injection-injury subtype is unique in that it involves a vasovagal fainting response rather than pure sympathetic arousal, requiring modified treatment approaches.

<image>Panel A: A diagram showing the five situation types defining agoraphobia with examples of each. Panel B: A Venn diagram illustrating the relationship between agoraphobia and panic disorder as separate but overlapping conditions. Panel C: A classification chart of specific phobia subtypes with common examples of each. Panel D: A comparison of typical anxiety response versus vasovagal response in blood-injection-injury phobia.</image>

V. Social Anxiety Disorder

Social anxiety disorder, also known as social phobia, involves marked fear or anxiety about one or more social situations in which the individual is exposed to possible scrutiny by others. Examples include social interactions such as having a conversation or meeting unfamiliar people, being observed such as eating or drinking in front of others, and performing in front of others such as giving a speech. The individual fears that they will act in a way or show anxiety symptoms that will be negatively evaluated, leading to embarrassment, humiliation, rejection, or offense to others. The social situations almost always provoke fear or anxiety and are avoided or endured with intense fear or anxiety.

The fear or avoidance in social anxiety disorder must be out of proportion to the actual threat posed by the social situation and must persist for at least six months. The fear, anxiety, or avoidance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning. The performance only specifier is used when the fear is restricted to speaking or performing in public, which tends to have a better prognosis and may respond well to as-needed beta-blocker treatment. The typical age of onset is early adolescence, with most cases beginning before age eighteen. The condition has a chronic course when untreated.

Clinical features of social anxiety disorder include characteristic physical symptoms, cognitive patterns, and behavioral responses. Physical symptoms in social situations include blushing, sweating, trembling voice, and tremor, which patients often fear will be noticeable to others and cause further embarrassment. Cognitive features include selective attention to social threat cues, negative interpretation of ambiguous social feedback, and post-event rumination about perceived social failures. Behavioral features include avoidance of feared social situations, reduced participation in social activities, and safety behaviors during social interactions such as avoiding eye contact, speaking quietly, or holding a drink to hide trembling hands.

Social anxiety disorder overlaps significantly with avoidant personality disorder, which also involves fear of negative evaluation and avoidance of social situations. The conditions may represent different severity levels of the same underlying pathology or may be distinct conditions that frequently co-occur. Comorbidity with other conditions is common, including depression, other anxiety disorders, and substance use disorders. Alcohol use disorder develops in some patients who discover that alcohol reduces social anxiety and begin using it as self-medication. The functional impairment from social anxiety disorder can be substantial, affecting educational achievement, occupational advancement, and development of intimate relationships.

<image>Panel A: A checklist of DSM-5 criteria for social anxiety disorder with duration and impairment requirements. Panel B: A diagram showing types of social situations that trigger anxiety including interaction, observation, and performance. Panel C: An illustration of the cycle of social anxiety including anticipatory anxiety, avoidance or distress, and post-event rumination. Panel D: A comorbidity chart showing conditions commonly co-occurring with social anxiety disorder.</image>

VI. Pharmacotherapy for Anxiety

Selective serotonin reuptake inhibitors represent the first-line pharmacological treatment for anxiety disorders due to their established efficacy, favorable tolerability profile, and low risk of dependence. Sertraline provides broad-spectrum efficacy for generalized anxiety disorder, panic disorder, and social anxiety disorder with relatively few drug interactions. Escitalopram is well-tolerated with simple dosing. Paroxetine has FDA approval for multiple anxiety disorders but has more prominent discontinuation effects. Fluoxetine provides good efficacy for panic disorder. A critical clinical point is that SSRIs may initially increase anxiety before therapeutic effects emerge, so patients should be warned to expect this and doses should be started low and increased gradually.

Serotonin-norepinephrine reuptake inhibitors provide an alternative first-line option with established efficacy across anxiety disorders. Venlafaxine extended-release has FDA approval for generalized anxiety disorder, social anxiety disorder, and panic disorder. Duloxetine has FDA approval for generalized anxiety disorder and may be particularly useful when comorbid chronic pain is present. Higher doses may be needed for full efficacy in anxiety disorders compared to depression. Blood pressure monitoring is advisable given the noradrenergic effects. The dual mechanism may provide advantages for patients who do not respond adequately to SSRIs alone.

Benzodiazepines provide rapid anxiolytic effects but carry significant risks that limit their appropriate use to short-term, adjunctive, or as-needed treatment rather than long-term monotherapy. Alprazolam is short-acting with higher abuse potential and more pronounced rebound anxiety between doses. Lorazepam has intermediate duration, no active metabolites, and predictable kinetics making it suitable for patients with hepatic impairment. Clonazepam has longer duration with less rebound anxiety. Risks of benzodiazepines include physical and psychological dependence, sedation impairing driving and cognition, falls particularly in elderly patients, and withdrawal seizures with abrupt discontinuation after prolonged use. Benzodiazepines should generally be avoided in patients with substance use disorder history.

Additional pharmacological options serve specific roles in anxiety treatment. Buspirone is effective for generalized anxiety disorder, is non-sedating, and lacks dependence risk, but requires several weeks to achieve full effect and does not provide acute anxiolysis. Pregabalin has efficacy for generalized anxiety disorder and is approved in Europe though used off-label in the United States. Hydroxyzine provides antihistamine-mediated sedation useful for as-needed anxiety relief. Beta-blockers such as propranolol are useful specifically for performance anxiety, blocking the peripheral physical manifestations of anxiety such as tremor and tachycardia but not effective for generalized anxiety. Gabapentin is used off-label for anxiety though evidence is more limited.

<image>Panel A: A comparison chart of SSRI medications showing dosing, FDA-approved indications, and distinguishing characteristics. Panel B: A diagram illustrating the timeline of SSRI effects showing initial anxiety increase followed by therapeutic improvement. Panel C: A comparison of benzodiazepines showing half-life, equivalent doses, and clinical considerations. Panel D: A decision algorithm for medication selection based on anxiety disorder type and patient factors.</image>

VII. Cognitive Behavioral Therapy for Anxiety

Cognitive behavioral therapy represents a first-line treatment for anxiety disorders with efficacy comparable to medication and superior durability of effects after treatment discontinuation. The treatment is based on the cognitive model which posits that maladaptive thoughts and behaviors maintain anxiety and that modifying these thoughts and behaviors reduces anxiety. Treatment is typically delivered in twelve to twenty sessions, though briefer protocols exist for specific phobias. The treatment is active and collaborative, requiring homework and practice between sessions. Skills learned during CBT continue to provide benefit after treatment ends, resulting in lower relapse rates compared to medication alone.

Cognitive techniques in CBT for anxiety target the maladaptive thought patterns that perpetuate anxious responding. Patients learn to identify automatic thoughts that occur during anxiety-provoking situations. Common cognitive distortions in anxiety include catastrophizing or expecting the worst possible outcome, probability overestimation or overestimating the likelihood of negative events, and mind-reading or assuming others are evaluating one negatively. Cognitive restructuring involves evaluating the evidence for and against anxious predictions and developing more balanced alternative thoughts. Behavioral experiments test the validity of anxious predictions by having patients deliberately engage in feared behaviors and observe outcomes.

Behavioral techniques, particularly exposure, form the core of CBT for anxiety disorders. Exposure involves systematic, repeated confrontation with feared stimuli or situations until anxiety decreases. The patient and therapist collaborate to construct a fear hierarchy ranking feared situations from least to most anxiety-provoking. Exposure begins with moderately challenging items and progresses to more difficult items as anxiety decreases. Exposure may be conducted in vivo with real situations, imaginally through mental imagery, or interoceptively by deliberately inducing feared physical sensations. Response prevention involves resisting urges to avoid, escape, or engage in safety behaviors during exposure.

Disorder-specific adaptations of CBT address the particular features of each anxiety disorder. For panic disorder, interoceptive exposure to feared physical sensations such as dizziness induced by spinning or breathlessness induced by breathing through a straw is combined with cognitive techniques targeting catastrophic misinterpretations of bodily sensations. For generalized anxiety disorder, techniques include scheduled worry time, problem-solving training, and interventions targeting intolerance of uncertainty. For social anxiety disorder, behavioral experiments testing social predictions combined with video feedback to correct distorted self-perception are particularly effective. For specific phobias, concentrated exposure over one or a few sessions is often sufficient.

<image>Panel A: A diagram showing the cognitive model of anxiety with relationships between situations, thoughts, physical sensations, and behaviors. Panel B: An illustration of a fear hierarchy showing progression from lower to higher anxiety items. Panel C: A comparison chart of exposure types including in vivo, imaginal, and interoceptive with indications for each. Panel D: A table showing disorder-specific CBT components for panic, GAD, social anxiety, and specific phobia.</image>

VIII. Exposure Therapy Principles

Exposure therapy rests on well-established principles of fear learning and extinction that explain how repeated contact with feared stimuli reduces anxiety over time. The habituation model proposes that anxiety naturally decreases when a person remains in contact with a feared stimulus without escaping, both within individual exposure sessions as immediate anxiety subsides and across sessions as baseline anxiety progressively decreases. More recent inhibitory learning models emphasize that exposure creates new learning that competes with and inhibits the original fear association rather than erasing it. Understanding these mechanisms informs optimal exposure procedures.

Multiple types of exposure address different features of anxiety across disorders. In vivo exposure involves direct confrontation with real feared objects or situations and is generally the most effective form of exposure. When in vivo exposure is not practical or ethical, imaginal exposure using detailed mental imagery of feared situations provides an alternative. Interoceptive exposure specifically targets fear of physical sensations by deliberately inducing those sensations through exercises such as hyperventilation, spinning, or straw breathing. Virtual reality exposure uses computer-generated environments to simulate feared situations and has established efficacy for specific phobias and PTSD with growing applications to other conditions.

Conducting effective exposure requires attention to several key principles. Exposures should be long enough for anxiety reduction to occur, with longer exposures generally more effective than shorter ones. Exposures should be repeated frequently, ideally daily during intensive treatment. Safety behaviors that prevent full engagement with the feared stimulus should be eliminated. Contexts should be varied to promote generalization of fear extinction to multiple settings. The patient should have an expectancy violation experience in which feared outcomes do not occur despite exposure to the feared stimulus. Cognitive processing of the exposure experience enhances learning.

Blood-injection-injury phobia requires modified exposure procedures because of its unique physiological response pattern. Unlike other phobias that involve sustained sympathetic activation with elevated heart rate and blood pressure, blood-injection-injury phobia involves a biphasic response with initial sympathetic activation followed by a parasympathetic rebound causing vasovagal syncope in some patients. Applied tension is a technique developed specifically for this phobia in which patients learn to tense large muscle groups to elevate blood pressure and prevent fainting during exposure to blood or injections. Combining applied tension with standard exposure procedures produces excellent outcomes for blood-injection-injury phobia.

<image>Panel A: A graph showing the habituation pattern of anxiety during exposure with within-session and between-session decrease. Panel B: A comparison of inhibitory learning versus habituation models of exposure. Panel C: A guide to conducting exposure showing principles of duration, frequency, safety behavior elimination, and context variation. Panel D: A diagram of the applied tension technique for blood-injection-injury phobia showing muscle tension to prevent vasovagal response.</image>

IX. Special Populations and Treatment Considerations

Anxiety disorders in children and adolescents require developmentally appropriate assessment and treatment approaches. Separation anxiety disorder, involving excessive fear concerning separation from attachment figures, is particularly common in childhood though it can persist into or begin in adulthood. Anxious children may present with behavioral manifestations such as tantrums, clinging, or school refusal rather than articulating internal experiences of worry. Treatment includes CBT adapted for the child's developmental level using age-appropriate materials, games, and activities. Family involvement is often essential, as parental accommodation of anxiety may inadvertently reinforce avoidance. SSRIs are effective for pediatric anxiety disorders when psychotherapy alone is insufficient.

Anxiety disorders in older adults present unique challenges in recognition and management. Older adults may present primarily with somatic complaints without recognizing or reporting psychological symptoms of anxiety. Medical conditions including cardiac arrhythmias, pulmonary disease, and hyperthyroidism become more common with age and must be ruled out as causes of anxiety symptoms. Medication selection requires attention to age-related pharmacokinetic changes and increased sensitivity to side effects. Benzodiazepines should generally be avoided in older adults due to risks of falls, hip fractures, cognitive impairment, and paradoxical disinhibition. SSRIs are effective but should be started at lower doses with slower titration. CBT is effective in older adults though may require adaptations for cognitive or sensory limitations.

Comorbid depression and anxiety present together in approximately half of patients with either condition, creating both diagnostic and treatment considerations. When both conditions are present, treatment of one often improves the other, as SSRIs and CBT are effective for both. However, the combination may indicate greater severity and poorer prognosis than either condition alone. Assessment should determine whether one condition preceded the other, as treating the primary condition may resolve the secondary condition. Depression may reduce engagement in exposure-based treatment for anxiety, suggesting the value of addressing depression first or concurrently.

Treatment-resistant anxiety requires systematic evaluation and stepped-care approaches. Before concluding that anxiety is treatment-resistant, clinicians should verify that previous treatments were adequate in terms of medication dose, duration, and adherence, and that CBT was delivered competently with sufficient exposure. Optimization strategies include increasing medication to maximum tolerated doses and extending treatment duration. Switching to a different SSRI or SNRI may succeed when the first fails. Augmentation strategies include adding buspirone, adding an atypical antipsychotic such as quetiapine, or combining medication with CBT. Specialty referral to an anxiety disorders clinic or expert may be appropriate for refractory cases.

<image>Panel A: A developmental adaptation guide showing modifications of anxiety assessment and treatment for children and adolescents. Panel B: A comparison of anxiety presentation and treatment considerations in older versus younger adults. Panel C: A treatment algorithm for comorbid depression and anxiety showing integrated approaches. Panel D: A stepped-care model for treatment-resistant anxiety showing optimization, switching, and augmentation strategies.</image>

X. Acute Anxiety Management

Assessment of acute anxiety presentations requires differentiation of anxiety symptoms from medical emergencies that may present similarly. Panic attacks produce symptoms including chest pain, shortness of breath, and dizziness that overlap with cardiac and pulmonary emergencies. Medical evaluation should consider cardiac conditions such as arrhythmias and myocardial infarction, pulmonary conditions such as pulmonary embolism and asthma, endocrine conditions such as hyperthyroidism and hypoglycemia, and substance intoxication or withdrawal. History of prior anxiety episodes, characteristic panic symptom pattern with peak within minutes and resolution within thirty minutes, and absence of objective medical abnormalities support an anxiety diagnosis, though medical causes should be ruled out particularly for first presentations or atypical features.

Acute panic attack management in the clinical setting focuses on reassurance, breathing techniques, and grounding while maintaining a calm environment. Reassurance should emphasize that panic attacks, while extremely uncomfortable, are not dangerous and will pass on their own, typically within minutes to half an hour. Slow, controlled breathing counteracts hyperventilation that may be perpetuating symptoms. The five-four-three-two-one grounding technique helps redirect attention away from internal anxiety sensations by having the patient identify five things they can see, four they can hear, three they can touch, two they can smell, and one they can taste. A calm, quiet environment reduces external stimulation. Benzodiazepines may be administered if non-pharmacological measures are insufficient.

The medical differential diagnosis of anxiety symptoms spans multiple organ systems and substance-related causes. Cardiac conditions presenting with anxiety-like symptoms include arrhythmias, myocardial infarction, and mitral valve prolapse, evaluated with ECG and cardiac biomarkers. Pulmonary embolism presents with dyspnea and may include chest pain and anxiety, evaluated with D-dimer and CT angiography if indicated. Hyperthyroidism causes anxiety, tremor, and tachycardia, evaluated with TSH. Hypoglycemia causes anxiety, tremor, and diaphoresis, evaluated with blood glucose. Pheochromocytoma causes episodic anxiety with hypertension. Caffeine excess and stimulant intoxication or withdrawal should be assessed by history.

Disposition following acute anxiety presentation depends on the clinical situation and underlying diagnosis. For a first panic attack with negative medical workup, disposition includes education about panic attacks, reassurance that they are not dangerous, and outpatient follow-up for evaluation and treatment. For patients with established anxiety disorders presenting with increased symptoms, medication adjustment and therapy referral are appropriate. Patients with severe functional impairment may benefit from intensive outpatient treatment. Suicidal ideation requires psychiatric evaluation and appropriate level of care. Documentation should include the clinical reasoning supporting an anxiety diagnosis and the rationale for disposition.

<image>Panel A: A diagnostic algorithm for acute anxiety presentations distinguishing panic attacks from medical emergencies. Panel B: A step-by-step guide for managing acute panic attacks with reassurance, breathing, and grounding techniques. Panel C: A differential diagnosis chart showing medical conditions mimicking anxiety with evaluation approaches for each. Panel D: A disposition decision tree based on presentation characteristics and severity.</image>

Summary

• Anxiety disorders are the most common mental disorders with twenty-eight to thirty percent lifetime prevalence; women affected twice as often as men
• GAD requires excessive worry about multiple domains for at least six months plus at least three of six somatic or cognitive symptoms
• Panic disorder requires recurrent unexpected panic attacks plus persistent concern about more attacks or maladaptive behavioral changes
• Panic attack involves at least four symptoms peaking within minutes including palpitations, sweating, dyspnea, chest pain, and fear of dying
• Social anxiety disorder involves fear of social situations where scrutiny may occur, with fear of acting embarrassingly; typical onset in early adolescence
• Agoraphobia involves fear of at least two situation types where escape might be difficult; can occur with or without panic disorder
• First-line medications include SSRIs starting low due to initial anxiety increase, and SNRIs; both require weeks for full effect
• Benzodiazepines provide rapid relief but carry risks of dependence, sedation, falls, and cognitive impairment; use short-term or as-needed only
• CBT is first-line with efficacy comparable to medication and better durability; exposure is the core behavioral technique
• Exposure involves systematic confrontation with feared stimuli until anxiety decreases; interoceptive exposure targets physical sensations in panic

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown